Antipsychotic medication and marked hyperprolactinaemia: Iatros or true prolactinoma?

Acta Paediatrica, International Journal of Paediatrics

Volumn 93, Issue 11, 2004, Pages 1543-1547

  Koves, I H ^a   Jarman, F C ^a   Cameron, Fergus J ^a  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

Adolescence; Antipsychotic agents; Children; Hyperprolactinaemia; Prolactinoma

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PROLACTIN; QUETIAPINE; RISPERIDONE;

ADOLESCENT; APPETITE DISORDER; ARTICLE; ATAXIA; BACKACHE; BREAKTHROUGH BLEEDING; CASE REPORT; FEMALE; GALACTORRHEA; HEADACHE; HUMAN; HYPERPROLACTINEMIA; IATROGENIC DISEASE; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; SIDE EFFECT; TREMOR; VISUAL IMPAIRMENT; VOMITING;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; HYPERPROLACTINEMIA; PITUITARY NEOPLASMS; PROLACTINOMA;

EID: 7644235209     PISSN: 08035253     EISSN: None     Source Type: Journal    
DOI: 10.1080/08035250410033853     Document Type: Article

References (15)

1. Krassas GE, Pontikides N, Kaltsas Th. Giant prolactinoma presented as unilateral exophthalmos in a prepubertal boy: response to cabergoline. Horm Res 1999; 52: 45-8
2. Fideleff HL, Boquete HR, Sequera A, Suarez M, Sobrado P, Giaccio A. Peripubertal prolactinomas: clinical presentation and long-term outcome with different therapeutic approaches. J Pediatr Endocrinol Metab 2000; 13: 261-7
3. Vance ML, Thorner MO. Prolactin: hyperprolactinemic syndromes and management. In: DeGroot LJ, editor. Endocrinology. Vol 1. 3rd ed. Philadelphia, London, Toronto, Montreal, Sydney, Tokyo: WB Saunders Company; 1995: 395-405
4. Efron D, Hiscock H, Sewell JR, Cranswick NE, Vance AL, Tyl Y, et al. Prescribing of psychotropic medications for children by Australian pediatricians and child psychiatrists. Pediatrics 2003; 111: 372-5
5. Woods SW, Martin A, Spector SG, McGlashan TH. Effects of development on olanzapine-associated adverse events. J Am Acad Child Adolesc Psychiatry 2002; 41: 1439-46
6. Smith S, Wheeler MJ, Murray R, O'Keane V. The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis. J Clin Psychopharmacol 2002; 22: 109-14
7. Galli-Tsinopoulou A, Nousia-Arvanitakis S, Mitsiakos G, Karamouzis M, Dimitriadis A. Osteopenia in children and adolescents with hyperprolactinemia. J Pediatr Endocrinol Metab 2000; 13: 439-41
8. Colao A, Loche S, Cappa M, Di Sarno A, Landi ML, Sarnacchiaro F, et al. Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up. J Clin Endocrinol Metab 1998; 83: 2777-80
9. Burtis CA, Ashwood ER, editors. Clinical chemistry. 2nd ed. Philadelphia, London, Toronto, Montreal, Sydney, Tokyo: WB Saunders Company; 1994: 1675
10. Weingarten JC, Thompson TL. The effect of thioridazine on prolactinoma growth in a schizophrenic man: a case report. Gen Hosp Psychiatry 1985; 7: 364-6
11. Pal JK, Sarino WA. Effect of risperidone on prolactinoma growth in a psychotic woman. Psychosom Med 2000; 62: 736-8
12. Wudarsky M, Nicholson R, Hamburger SD, Spechler L, Gochman P, Bedwell J, et al. Elevated prolactin in pediatric patients on typical and atypical antipsychotics. J Child Adolesc Psychopharmacol 1999; 9: 239-45
13. Cohen LG, Biederman J. Treatment of risperidone-induced hyperprolactinaemia with a dopamine agonist in children. J Child Adolesc Psychopharmacol 2001; 11: 435-40
14. Peuskens J, Link CG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997; 96: 265-73
15. Kaptein EM, Spencer CA, Kamiel MB, Nicoloff JT. Prolonged dopamine administration and thyroid hormone economy in normal and critically ill subjects. J Clin Endocrinol Metab 1980; 51: 387-93